EXAI News and Press, Exscientia Limited From 05/24/23

Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below. Exscientia will host a conference call Wednesday, May 24 at 1:30 p.m. BST / 8:30 a.m. EDT. ...

Latest technology advances to innovate drug design, discovery and development Novel automated discovery laboratory on track to open in 2023 Exscientia plc (Nasdaq: EXAI) today announced two abstracts for oral and poster presentation, as well as the closing keynote to be delivere...

2023-05-18 01:44:16 ET Summary Exscientia's AI-driven drug discovery platform has positioned the company at the forefront of precision medicine, revolutionizing the way new therapies are developed. Exscientia's pipeline has precision oncology programs, such as EXS74539 and EXS7356...

2023-05-17 19:43:06 ET Summary Pardes Biosciences Seeking Strategic Alternatives. Pardes’ Pipeline is depleted. All-Star management team in place. Significant cash available. Pardes Biosciences Seeking Strategic Alternatives Could See Consolidation Par...

Second prestigious honour recognising “exceptional contributions to biomedical and health science” Follows “double” Prix Galien award for Exscientia Professor Andrew Hopkins FRS FRSE, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has b...

Company to host conference call and webcast on May 24, 2023, at 1:30 p.m. BST / 8:30 a.m. EDT Exscientia plc (Nasdaq: EXAI) will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 24, 2023, before the open of U.S. markets. The Company will host a conf...

Third clinical molecule from collaboration with Sumitomo Pharma to enter Phase 1 trials DSP-2342, a dual 5-HT2A/5-HT7 antagonist to be assessed in psychiatric disease Exscientia plc (Nasdaq: EXAI) today announced that Sumitomo Pharma Co., Ltd. (‘Su...

Changing the world through exceptional science and technology Professor Andrew Hopkins DPhil LLD FRSE, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has been elected a Fellow of the Royal Society, the world’s oldest and most influential scientific society. Andrew ...

— Renowned thought leader in computational biology and data science for cancer research — — Over 180 publications on the evolutionary dynamics of cancer initiation, progression, response to therapy and emergence of resistance — Exscientia plc (Nasdaq:...

- Includes recent advancements from precision designed compounds - - Functional personalised medicine platform unveiling unique adenosine biomarker to enrich for patients more likely to respond to treatment - Exscientia plc (Nasdaq: EXAI) today announced four pre...